Work

Editorial: stratifying risk of adverse outcomes in cirrhosis—the Hepquant SHUNT test. Authors' reply

Year: 2021

Type: editorial

Abstract: LINKED CONTENT This article is linked to Fallahzadeh et al and Maan & Sonneveld papers. To view these articles, visit https://doi.org/10.1111/apt.16283 and https://doi.org/10.1111/apt.16299

Source: Alimentary Pharmacology & Therapeutics

DOI: 10.1111/apt.16311

Authors: Sumeet K. Asrani, Gregory T. Everson

Institutions: Baylor University Medical Center, HepQuant (United States), University of Colorado Anschutz, University of Colorado Denver

Language: English

Topic: Liver Disease and Transplantation

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3138907436

Cites: 5

Cited by: 1

Related to: 10